Should I Buy GMRE? GMRE 2026 Analysis

Should You Buy Global Medical REIT Inc (GMRE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

36.630

1 Day change

-0.22%

52 Week Range

45.750

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: price is pressing into near-term resistance (~35.97) with short-term momentum looking stretched (RSI ~68.9) while MACD remains slightly negative.
Probabilistic trend read is modestly bearish (next day/week/month skew negative), which is not ideal if you want immediate upside.
Insider buying is a meaningful positive, but it’s currently outweighed by weak profitability in the latest reported quarter and a neutral Street stance.
Intellectia Proprietary Trading Signals
AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/momentum: MACD histogram is negative (-0.0359) though contracting, implying downside momentum is fading but not yet flipped bullish.
RSI(6) at 68.871: nearing overbought; upside from here is more prone to pullbacks than clean breakouts.
Moving averages: converging, which often precedes a larger move but does not confirm direction; current setup is not a clear “trend up” signal.
Levels: Pivot 35.02; immediate resistance R1 35.965 (price ~35.88 is very close), next R2 36.549. Support S1 34.074 then S2 33.49.
Near-term odds signal: pattern-based read suggests ~70% chance of slight drift lower (-0.2% next day, -0.74% next week, -1.85% next month).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/sentiment: Open interest put/call ratio at 0.8 is mildly bullish (more calls than puts in OI).
Activity: Options volume is extremely light (only 5 contracts; put volume 0), so sentiment read from volume is low-confidence.
Volatility: 30D IV 36.27 vs historical vol 21.84 (IV elevated); IV percentile ~66.93 suggests options are priced on the expensive side.
Today vs averages: Volume/interest metrics show jumps vs 30D averages, but on a tiny base—can be noise.

Technical Summary

Sell

Buy

Positive Catalysts

- Insider activity: insiders are buying aggressively (buying amount up ~4132% over the last month), often a supportive signal.
- Corporate action/news: rebranding to “Chiron Real Estate” with new ticker “XRN” effective Feb 23 may attract fresh attention/flows.
- Upcoming event: QDEC 2025 earnings on 2026-03-03 (after hours) can be a catalyst if results/guide surprise positively.
- Analyst target still above current price: latest cited target $41 (even after being lowered) implies upside if fundamentals stabilize.

Neutral/Negative Catalysts

- Profitability deterioration: latest reported quarter shows net income and EPS sharply worse YoY (loss widened materially), which can cap upside.
- Technical near resistance: current price is just below R1 (~35.965), increasing the odds of a short-term stall/pullback.
- Options market is thin: low liquidity reduces the reliability of options-based sentiment and can increase gap risk around events.
- Analyst stance is Neutral and the firm cited “tough capital markets” and potential asset recycling pressure (headwind for REIT execution).
- Influential/political flows: no recent congress trading data available; no politician/influential figure transactions were provided.

Financial Performance

Latest quarter reported: 2025/Q3.
Revenue: 37.229M, up 8.65% YoY (top-line growth is positive).
Net income: -6.001M, down -435.06% YoY (loss widened significantly).
EPS: -0.45, down -421.43% YoY (meaningfully worse profitability per share).
Takeaway: growth in revenue is being offset by a sharp profitability decline—fundamentals are not currently confirming a strong “buy now” setup.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent change: (2025-11-11) Baird lowered price target to $41 from $45 and maintained a Neutral rating.
Street pros view (implied): upside potential to target and possible corporate actions/portfolio moves can help.
Street cons view (implied): capital markets remain challenging for REITs; asset recycling and funding conditions may limit near-term performance; Neutral rating signals no urgency to buy at current levels.

3 Analyst Rating

Wall Street analysts forecast GMRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMRE is 37.83 USD with a low forecast of 35 USD and a high forecast of 41 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 36.710

Low

Averages

37.83

High

Current: 36.710

Low

Averages

37.83

High

Baird

Neutral

downgrade

$45 -> $41

AI Analysis

2025-11-11

Reason

Baird

Price Target

$45 -> $41

AI Analysis

2025-11-11

downgrade

Neutral

Reason

Baird lowered the firm's price target on Global Medical REIT to $41 from $45 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results which suggest the tough capital markets may lead to asset recycling.

Alliance Global Partners

Gaurav Mehta

Buy

downgrade

2025-05-29

Reason

Alliance Global Partners

Gaurav Mehta

Price Target

2025-05-29

downgrade

Buy

Reason

Alliance Global Partners analyst Gaurav Mehta lowered the firm's price target on Global Medical REIT to $8.50 from $9.50 and keeps a Buy rating on the shares. The company lowered its common dividend by 28.6%, which is the "right step" given the prior dividend was not covered by 2025 and 2026 estimates, the analyst tells investors in a research note. Going forward, the firm believes improved portfolio performance, including an improvement in occupancy, resolving of tenant issues such as Prospect Medical and the closure of the CEO search could be a positive catalyst for the stock.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GMRE

Unlock Now

GMRE Should I Buy

GMRE Should I Buy

Should You Buy Global Medical REIT Inc (GMRE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch